Skip to content

Released Nov 5, 2026, after the close

10-Q filed Nov 9, 2026, 40 days after period end · 0001628280-26-072290

Q3 2026 · 10-Q
Revenue$27.71M−5.7% vs Q3 2025+37.5% vs Q2 2026
Net Income-$40.98MN/M vs Q3 2025N/M vs Q2 2026
EPS, diluted—
Operating Income-$43,633,000N/M
Operating Cash Flowderived-$28,348,000N/M
Free Cash Flowderived-$30,348,000N/M
Margins · derived
Operating margin-157.5%+122.7 pt vs Q3 2025
Net margin-147.9%+127.0 pt vs Q3 2025

What the release said

Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkgobioworks.com) and its news site (https://investors.ginkgobioworks.com/news).

Ginkgo reported third quarter 2026 results and announced the sale of an autonomous lab to a top-tier pharma company, Novo, at Novo's new Waltham, Massachusetts R&D site.23

Third quarter 2026 revenue was $28 million, compared to $29 million a year earlier, while GAAP net loss from continuing operations was ($41) million versus ($73) million.456

Cash, cash equivalents and marketable securities were $285 million as of September 30, 2026, after third quarter 2026 cash burn of $27 million.78

A subcontract worth up to $17.5 million under ARPA-H GIVE will put RACs and Catalyst into RNA-medicine manufacturing for the first time.9

Ginkgo reaffirmed expected total cash burn of ($150)-($125) million in 2026.10

Third quarter 2026 revenue
$28 million Compared to $29 million in the comparable prior year period, a decrease of 6%4
Third quarter 2026 GAAP net loss from continuing operations
($41) million Compared to ($73) million in the comparable prior year period5
Third quarter 2026 Adjusted EBITDA
($22) million Improved from ($53) million in the comparable prior year period6
Cash, cash equivalents and marketable securities
$285 million As of September 30, 20267
Full year 2026 expected total cash burn
($150)-($125) million Reaffirmed outlook range for 202610
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$27.71M$29.38M$89.05M$55.43M
Net Income-$40.98M-$80.76M-$56.40M-$302.89M
EPS Diluted—-$1.45-$1.08-$6.21

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR